Anna Berkenblit
Net Worth
Last updated:
What is Anna Berkenblit net worth?
The estimated net worth of Dr. Anna Berkenblit is at least $5,468,083 as of 24 Feb 2020. He has earned $334,163 from insider trading and has received compensation worth at least $5,133,920 in ImmunoGen, Inc..
What is the salary of Anna Berkenblit?
Dr. Anna Berkenblit salary is $641,740 per year as Senior Vice President & Chief Medical Officer in ImmunoGen, Inc..
How old is Anna Berkenblit?
Dr. Anna Berkenblit is 55 years old, born in 1970.
What stocks does Anna Berkenblit currently own?
As insider, Dr. Anna Berkenblit owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ImmunoGen, Inc. (IMGN) | Senior Vice President & Chief Medical Officer | 98,089 | $0 | $0 |
What does ImmunoGen, Inc. do?
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Anna Berkenblit insider trading
ImmunoGen, Inc.
Dr. Anna Berkenblit has made 6 insider trades between 2017-2020, according to the Form 4 filled with the SEC. Most recently he sold 25,803 units of IMGN stock worth $128,757 on 24 Feb 2020.
The largest trade he's ever made was exercising 25,803 units of IMGN stock on 24 Feb 2020. As of 24 Feb 2020 he still owns at least 98,089 units of IMGN stock.
ImmunoGen key executives
ImmunoGen, Inc. executives and other stock owners filed with the SEC:
- Dr. Anna Berkenblit (55) Senior Vice President & Chief Medical Officer
- Dr. Theresa G. Wingrove (67) Senior Vice President of Regulatory Affairs & Quality
- Mr. Mark Joseph Enyedy (61) Pres, Chief Executive Officer & Director
- Ms. Stacy A. Coen (54) Senior Vice President & Chief Bus. Officer
- Ms. Susan Altschuller Ph.D. (43) Senior Vice President & Chief Financial Officer